{
    "hands_on_practices": [
        {
            "introduction": "The pathogenesis of any viral disease begins with the virus successfully entering a host cell, a process often likened to a specific key fitting a lock. This exercise explores how variations in host cell \"locks\"—in this case, the CCR5 co-receptor—can prevent the HIV \"key\" from working. By reasoning from first principles of receptor biology, you will unravel the molecular basis for the remarkable resistance to HIV seen in individuals with the CCR5-$\\Delta$32 genetic mutation, a cornerstone case study in human genetics and infectious disease .",
            "id": "4660160",
            "problem": "A cohort study follows individuals who are homozygous for the C-C chemokine receptor 5 (CCR5)-$\\Delta$32 deletion. Investigators note a markedly reduced incidence of acquisition of Human Immunodeficiency Virus type 1 (HIV-1) after mucosal exposure, but documented cases of infection still occur, particularly after parenteral exposures. Using first principles of receptor–ligand interactions and the sequential binding mechanism required for retroviral entry, reason from the following foundational facts to identify the best explanation(s):\n\nFoundational facts:\n- Viral entry requires specific binding of a viral attachment protein to a primary receptor, followed by engagement of a necessary coreceptor, before membrane fusion can proceed. For HIV-1, the envelope glycoprotein 120 (gp120) first binds to the cluster of differentiation 4 (CD4) receptor and then engages a chemokine coreceptor, most commonly C-C chemokine receptor 5 (CCR5) or C-X-C chemokine receptor 4 (CXCR4).\n- Absence of a required receptor on the host cell surface lowers the probability of productive binding to approximately zero because receptor–ligand complementarity is necessary for the conformational changes that enable fusion.\n- Tissue tropism reflects the distribution of host receptors: memory T cells and macrophages at mucosal surfaces commonly express CCR5, whereas naive T cells in blood and lymphoid organs commonly express CXCR4.\n\nWhich of the following statements are most consistent with these principles and explain both why CCR5-$\\Delta$32 homozygosity prevents entry of R5-tropic viruses at mucosa and why residual risk remains due to X4 strains or parenteral exposure?\n\nA. In CCR5-$\\Delta$32 homozygotes, the truncated CCR5 does not reach the plasma membrane, so after gp120 binds CD4, there is no available CCR5 to engage; without this coreceptor–ligand interaction, the conformational cascade in the envelope required for fusion cannot occur. This blocks entry of R5-tropic strains that require CCR5.\n\nB. CCR5-$\\Delta$32 alters the structure of CD4, reducing gp120 affinity for all HIV-1 strains; resistance is therefore due to reduced primary receptor binding, and any breakthrough infection implies compensatory gp120 mutations that restore CD4 binding.\n\nC. The CCR5-$\\Delta$32 genotype causes constitutive upregulation of intracellular restriction factors that block reverse transcription, providing broad resistance to both R5 and X4 strains; parenteral inoculation overcomes this by delivering a higher number of virions that saturate these restriction pathways.\n\nD. X4-tropic and dual-tropic strains can still enter cells by engaging CXCR4 after gp120–CD4 binding, independent of CCR5; parenteral exposure bypasses mucosal selection for R5 variants and delivers virus directly into compartments rich in CXCR4-expressing naive T cells, increasing the chance that an X4 or dual-tropic variant initiates infection.\n\nE. Parenteral inoculation creates sufficient membrane tension to allow gp120–CD4 binding to drive fusion without any chemokine coreceptor, explaining breakthrough infections despite absence of surface CCR5.\n\nSelect all that apply.",
            "solution": "The problem statement is subjected to validation before proceeding with a solution.\n\n### Step 1: Extract Givens\n- A cohort study on individuals homozygous for the C-C chemokine receptor 5 (CCR5)-$\\Delta$32 deletion shows:\n    - Markedly reduced incidence of Human Immunodeficiency Virus type 1 (HIV-1) acquisition after mucosal exposure.\n    - Documented cases of infection still occur, particularly after parenteral exposures.\n- Foundational Fact $1$: HIV-1 entry is a sequential process. The envelope glycoprotein 120 (gp120) first binds to the primary cluster of differentiation 4 (CD4) receptor. This is followed by engagement of a chemokine coreceptor, most commonly C-C chemokine receptor 5 (CCR5) or C-X-C chemokine receptor 4 (CXCR4), which is necessary for membrane fusion.\n- Foundational Fact $2$: The absence of a required receptor on the host cell surface reduces the probability of productive binding to approximately $0$, because receptor-ligand interaction is essential for the conformational changes that enable fusion.\n- Foundational Fact $3$: Tissue tropism is determined by receptor distribution.\n    - Memory T cells and macrophages at mucosal surfaces commonly express CCR5.\n    - Naive T cells in blood and lymphoid organs commonly express CXCR4.\n- The question asks for the statement(s) that are most consistent with these principles and explain both the protection seen in CCR5-$\\Delta$32 homozygotes against R5-tropic viruses and the residual risk of infection from X4-tropic strains or via parenteral exposure.\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is assessed for validity.\n- **Scientifically Grounded:** The problem is based on established, fundamental principles of virology and immunology concerning HIV-1 pathogenesis. The role of CCR5 and the CCR5-$\\Delta$32 mutation is a cornerstone of HIV-1 research and a factual example of host genetics influencing viral susceptibility. All foundational facts are scientifically accurate.\n- **Well-Posed:** The problem is clearly structured. It provides a set of facts and asks for a logical deduction to explain a specific, real-world phenomenon. A unique set of explanations can be derived by applying the provided principles.\n- **Objective:** The language is technical, precise, and free of subjective or biased content.\n- **Completeness and Consistency:** The provided facts are sufficient to construct a complete explanation for both parts of the observation (resistance and breakthrough infection). The facts are internally consistent and do not contradict one another.\n- **Realism:** The scenario is not only realistic but is a classic case study in medical microbiology.\n- **Structure:** The problem is logically structured, moving from observation to foundational principles to a question requiring synthesis.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. It is scientifically sound, well-posed, and internally consistent. I will now proceed to derive the solution from the given principles.\n\n### Derivation from First Principles\nThe problem requires an explanation for two phenomena in individuals homozygous for the CCR5-$\\Delta$32 deletion: $1$) high resistance to HIV-1 infection, particularly at mucosal surfaces, and $2$) residual risk of infection, especially via parenteral routes.\n\n**1. Explanation of Resistance to Mucosal HIV-1 Transmission:**\nAccording to Foundational Fact $1$, HIV-1 entry is a two-step binding process: gp120 binds to CD4, then to a coreceptor (CCR5 or CXCR4). Foundational Fact $3$ states that the virus typically encountered at mucosal surfaces uses CCR5 as a coreceptor (these are known as R5-tropic viruses) because the target cells there (memory T cells, macrophages) express CCR5.\nIndividuals homozygous for the CCR5-$\\Delta$32 deletion lack a functional CCR5 protein on their cell surfaces. The $\\Delta$32 mutation results in a truncated, non-functional protein that is not transported to the plasma membrane.\nApplying Foundational Fact $2$: for an R5-tropic virus, the absence of its required coreceptor, CCR5, on the target cell surface means the second step of the entry process cannot occur. Even if the virus successfully binds to CD4, the subsequent engagement with CCR5 is impossible. This failure to engage the coreceptor prevents the necessary conformational changes in the viral envelope glycoproteins required for membrane fusion. Consequently, viral entry is blocked, leading to a markedly reduced incidence of infection.\n\n**2. Explanation of Residual Risk and Breakthrough Infections:**\nThe resistance mechanism described above is specific to viruses that require CCR5. Foundational Fact $1$ establishes that some HIV-1 variants can use an alternative coreceptor, CXCR4 (these are X4-tropic viruses), or both (dual-tropic viruses). The CCR5-$\\Delta$32 mutation has no effect on the CXCR4 gene or its protein product. Therefore, cells expressing both CD4 and CXCR4 remain susceptible to infection by X4-tropic or dual-tropic HIV-1 strains.\nFoundational Fact $3$ states that naive T cells, which are abundant in blood and lymphoid organs, commonly express CXCR4.\nThe problem notes that breakthrough infections are particularly associated with parenteral exposure (e.g., intravenous drug use, blood transfusion). Parenteral exposure introduces the virus directly into the bloodstream, bypassing the mucosal barrier where R5-tropic viruses are predominantly selected for transmission. This direct inoculation into a compartment rich in CXCR4-expressing naive T cells significantly increases the probability that a pre-existing or newly mutated X4-tropic or dual-tropic variant within the viral inoculum will find a suitable target cell and successfully initiate an infection.\n\n**Conclusion of Derivation:** The complete explanation must incorporate both the blockage of R5-tropic virus entry due to the absence of surface CCR5 and the ability of X4/dual-tropic viruses to use the alternative CXCR4 coreceptor, a risk amplified by parenteral exposure.\n\n### Option-by-Option Analysis\n\n**A. In CCR5-$\\Delta$32 homozygotes, the truncated CCR5 does not reach the plasma membrane, so after gp120 binds CD4, there is no available CCR5 to engage; without this coreceptor–ligand interaction, the conformational cascade in the envelope required for fusion cannot occur. This blocks entry of R5-tropic strains that require CCR5.**\n- **Justification:** This statement is a precise and accurate description of the molecular mechanism of resistance. It correctly states that the CCR5-$\\Delta$32 mutation leads to a lack of surface CCR5. It then correctly applies the principles of sequential binding (Fact $1$) and the necessity of receptor-ligand interaction for fusion (Fact $2$) to explain why R5-tropic viruses are blocked. This perfectly accounts for the first part of the phenomenon.\n- **Verdict:** **Correct**.\n\n**B. CCR5-$\\Delta$32 alters the structure of CD4, reducing gp120 affinity for all HIV-1 strains; resistance is therefore due to reduced primary receptor binding, and any breakthrough infection implies compensatory gp120 mutations that restore CD4 binding.**\n- **Justification:** This statement is factually incorrect. The gene for CCR5 is distinct from the gene for CD4. A mutation in the CCR5 gene does not alter the structure or function of the CD4 protein. This contradicts the provided principle that gp120 first binds to CD4 and then engages a separate coreceptor. The mechanism of resistance is at the coreceptor level, not the primary receptor level.\n- **Verdict:** **Incorrect**.\n\n**C. The CCR5-$\\Delta$32 genotype causes constitutive upregulation of intracellular restriction factors that block reverse transcription, providing broad resistance to both R5 and X4 strains; parenteral inoculation overcomes this by delivering a higher number of virions that saturate these restriction pathways.**\n- **Justification:** This statement proposes a mechanism that is inconsistent with the provided foundational facts, which focus exclusively on the receptor-mediated entry process. The primary resistance conferred by CCR5-$\\Delta$32 is at the level of viral entry, not a post-entry event like reverse transcription. While restriction factors exist, they are not the principal explanation for the profound resistance observed in this specific genetic context.\n- **Verdict:** **Incorrect**.\n\n**D. X4-tropic and dual-tropic strains can still enter cells by engaging CXCR4 after gp120–CD4 binding, independent of CCR5; parenteral exposure bypasses mucosal selection for R5 variants and delivers virus directly into compartments rich in CXCR4-expressing naive T cells, increasing the chance that an X4 or dual-tropic variant initiates infection.**\n- **Justification:** This statement correctly explains the residual risk and the mechanism of breakthrough infections. It accurately invokes the alternative CXCR4 coreceptor (Fact $1$), links its usage to specific cell populations found in blood (Fact $3$), and correctly reasons that parenteral exposure provides access to these compartments. This perfectly accounts for the second part of the phenomenon.\n- **Verdict:** **Correct**.\n\n**E. Parenteral inoculation creates sufficient membrane tension to allow gp120–CD4 binding to drive fusion without any chemokine coreceptor, explaining breakthrough infections despite absence of surface CCR5.**\n- **Justification:** This statement proposes a biophysically implausible mechanism that directly contradicts Foundational Fact $1$, which states that engagement of a *necessary coreceptor* is required for fusion. The idea that mechanical force (\"membrane tension\") can replace the specific, high-affinity molecular interaction and subsequent conformational changes induced by coreceptor binding is not supported by the given principles or established virology.\n- **Verdict:** **Incorrect**.",
            "answer": "$$\\boxed{AD}$$"
        },
        {
            "introduction": "Once an infection is established, the defining feature of HIV pathogenesis is its relentless and rapid replication cycle, which serves as an engine for genetic variation and immune escape. This practice provides a quantitative lens through which to view this process, asking you to calculate the virus's incredibly short generation time from fundamental kinetic data . This calculation directly connects the microscopic world of viral dynamics to the macroscopic progression of Acquired Immunodeficiency Syndrome (AIDS), illustrating how sheer speed and volume of replication drive the disease.",
            "id": "4660171",
            "problem": "A patient with chronic Human Immunodeficiency Virus (HIV) infection progressing toward Acquired Immunodeficiency Syndrome (AIDS) exhibits rapid plasma viral dynamics consistent with first-order (memoryless) clearance of free virions. Let the free-virus clearance be characterized by a rate constant $c$ with units day$^{-1}$, and let the daily production of virions from infected cells in plasma be $P$. You are given that $P = 1.00 \\times 10^{9}$ virions/day and that independent kinetic estimates under antiretroviral therapy (ART) blockade of new production yield a free-virus clearance rate of $c = 23$ day$^{-1}$.\n\nUsing fundamental properties of first-order processes and steady-state balance arguments that do not assume any shortcut formulas, determine the mean generation time of free virions in hours and the daily turnover (the number of plasma virions cleared per day at steady state, equivalently produced per day). Round your answers to three significant figures. Express the generation time in hours and the daily turnover in virions/day. Finally, explain briefly (qualitatively, in one or two sentences) how these values contribute to rapid within-host evolution in HIV pathogenesis leading to AIDS, based on core principles of microbial replication and mutation.",
            "solution": "The problem statement has been validated and is deemed scientifically grounded, well-posed, and internally consistent. The parameters provided are standard in the field of viral dynamics for HIV-1. We may proceed with the solution.\n\nThe problem asks for two quantitative values—the mean generation time of free virions and the daily turnover at steady state—and one qualitative explanation. We will address each in order, deriving them from fundamental principles as requested.\n\nFirst, we determine the mean generation time of a free virion. The problem states that virion clearance is a first-order, memoryless process. This can be described by the differential equation for the number of virions, $V$, subject only to clearance:\n$$\n\\frac{dV}{dt} = -cV\n$$\nwhere $c$ is the first-order rate constant for clearance, given as $c = 23 \\text{ day}^{-1}$. This equation describes exponential decay. The solution shows that the number of virions from an initial population $V_0$ remaining at time $t$ is $V(t) = V_0 \\exp(-ct)$.\n\nThe probability that a given virion survives until at least time $t$ is the survival function, $S(t) = \\frac{V(t)}{V_0} = \\exp(-ct)$. The lifetime of a virion is a random variable, and its probability density function, $p(t)$, is given by the negative derivative of the survival function:\n$$\np(t) = -\\frac{dS(t)}{dt} = -\\frac{d}{dt}\\exp(-ct) = c \\exp(-ct)\n$$\nThe mean generation time, which is equivalent to the mean lifetime $\\langle t \\rangle$, is the expectation value of the lifetime $t$, calculated by integrating $t$ weighted by its probability density function over all possible lifetimes from $0$ to $\\infty$:\n$$\n\\langle t \\rangle = \\int_0^\\infty t \\cdot p(t) \\, dt = \\int_0^\\infty t \\cdot c \\exp(-ct) \\, dt\n$$\nTo solve this integral, we use integration by parts, $\\int u \\, dv = uv - \\int v \\, du$. Let $u = t$ and $dv = c \\exp(-ct) \\, dt$. Then $du = dt$ and $v = -\\exp(-ct)$.\n$$\n\\langle t \\rangle = \\left[ t(-\\exp(-ct)) \\right]_0^\\infty - \\int_0^\\infty (-\\exp(-ct)) \\, dt\n$$\nThe first term evaluates to $0$, since $\\lim_{t \\to \\infty} (-t \\exp(-ct)) = 0$ and $(0 \\cdot (-\\exp(0))) = 0$. We are left with:\n$$\n\\langle t \\rangle = \\int_0^\\infty \\exp(-ct) \\, dt = \\left[ -\\frac{1}{c} \\exp(-ct) \\right]_0^\\infty\n$$\n$$\n\\langle t \\rangle = \\left( -\\frac{1}{c} \\exp(-\\infty) \\right) - \\left( -\\frac{1}{c} \\exp(0) \\right) = (0) - \\left(-\\frac{1}{c}\\right) = \\frac{1}{c}\n$$\nThus, the mean generation time is the reciprocal of the clearance rate constant. Given $c = 23 \\text{ day}^{-1}$:\n$$\n\\langle t \\rangle = \\frac{1}{23} \\text{ days}\n$$\nThe problem requires the answer in hours. Since there are $24$ hours in a day:\n$$\n\\langle t \\rangle_{\\text{hours}} = \\frac{1}{23} \\text{ days} \\times \\frac{24 \\text{ hours}}{1 \\text{ day}} = \\frac{24}{23} \\text{ hours} \\approx 1.04347... \\text{ hours}\n$$\nRounding to three significant figures, the mean generation time is $1.04$ hours.\n\nSecond, we determine the daily turnover. The full dynamic model for the number of free virions $V$ in the plasma includes both production, $P$, and clearance, $cV$:\n$$\n\\frac{dV}{dt} = P - cV\n$$\nAt steady state, the population of virions is constant, which means its rate of change is zero: $\\frac{dV}{dt} = 0$. Applying this condition to the dynamic equation:\n$$\n0 = P - cV_{ss}\n$$\nwhere $V_{ss}$ is the steady-state number of virions. This equation reveals a fundamental balance at steady state: the rate of production equals the rate of clearance.\n$$\nP = cV_{ss}\n$$\nThe \"daily turnover\" is defined as the total number of virions cleared per day. The rate of clearance is the term $cV$. At steady state, this is $cV_{ss}$. From our balance equation, this is simply equal to the production rate, $P$. The problem provides the production rate as $P = 1.00 \\times 10^9$ virions/day. Therefore, the daily turnover at steady state is:\n$$\n\\text{Daily Turnover} = P = 1.00 \\times 10^9 \\text{ virions/day}\n$$\n\nFinally, we provide the qualitative explanation. The prodigious daily turnover of $1.00 \\times 10^9$ virions and the extremely short generation time of approximately $1.04$ hours mean that a vast number of viral replication cycles are completed daily. Because HIV's reverse transcriptase enzyme is error-prone and lacks a proofreading mechanism, this massive and rapid replication generates enormous genetic diversity, providing the raw material for natural selection to drive the rapid evolution of immune-escape and drug-resistant variants central to AIDS pathogenesis.",
            "answer": "$$\n\\boxed{\\begin{pmatrix} 1.04 & 1.00 \\times 10^{9} \\end{pmatrix}}\n$$"
        },
        {
            "introduction": "A central challenge in HIV pathogenesis is the virus's ability to establish a persistent, latent reservoir that is invisible to the immune system and unaffected by most antiviral drugs. This problem tackles the long-term dynamics of this reservoir, a critical hurdle for developing a cure for HIV. By modeling the differential decay rates of replication-competent versus defective proviruses, you will gain insight into the stability of the latent reservoir and understand the quantitative rationale behind the ongoing search for curative strategies .",
            "id": "4660133",
            "problem": "A longitudinal cohort study of individuals with Human Immunodeficiency Virus (HIV) on suppressive Antiretroviral Therapy (ART) measures the intactness of proviral genomes using single-genome, full-length sequencing of proviruses recovered from resting memory CD4 T cells. Intact proviruses are used here as a proxy for replication-competent proviruses; assume all intact proviruses are replication-competent for the purpose of this calculation. Under sustained viral suppression, assume that new infection events are negligible and that loss of infected cells follows first-order kinetics with a constant per-cell loss rate within each class (intact versus defective). \n\nAt ART initiation time $t=0$ years, the per-million-cell counts are: intact proviruses $I(0)=120$ and defective proviruses $D(0)=4880$. At $t=3$ years on ART, the counts are measured as $I(3)=60$ and $D(3)=4392$. \n\nUsing only the assumptions above and these measurements:\n- Infer the first-order rate constants for loss of intact and defective proviruses.\n- Using those inferred dynamics, compute the fraction of the total proviral reservoir that is replication-competent (i.e., intact) at $t=6$ years on ART, defined as \n$$f(6)=\\frac{I(6)}{I(6)+D(6)}.$$\n\nExpress your final answer as a unitless decimal rounded to four significant figures. In your reasoning, begin from the stated first-order loss assumption and do not assume any form for the solutions until derived from that assumption. Also, briefly interpret the biological implications of your result for cure strategies in terms of relative decay rates and practical timelines, but note that only $f(6)$ is required as the final numerical answer.",
            "solution": "The problem statement is evaluated as scientifically grounded, well-posed, and objective. All necessary data and assumptions for a unique solution are provided and are consistent with established models of proviral decay in HIV research. The problem is therefore valid.\n\nThe problem states that the loss of intact and defective proviruses follows first-order kinetics. This assumption can be formulated as a pair of ordinary differential equations. Let $I(t)$ be the concentration of intact proviruses and $D(t)$ be the concentration of defective proviruses at time $t$ in years. The rate of change for each population is proportional to its current size.\n\nFor the intact proviral population, we have:\n$$ \\frac{dI(t)}{dt} = -k_I I(t) $$\nwhere $k_I$ is the first-order rate constant for the loss of intact proviruses, with units of years$^{-1}$.\n\nFor the defective proviral population, we have:\n$$ \\frac{dD(t)}{dt} = -k_D D(t) $$\nwhere $k_D$ is the first-order rate constant for the loss of defective proviruses, with units of years$^{-1}$.\n\nThese are standard separable first-order linear differential equations. The general solution for an equation of the form $\\frac{dN}{dt} = -kN$ is found by separating variables and integrating:\n$$ \\int_{N(0)}^{N(t)} \\frac{1}{N'} dN' = \\int_0^t -k dt' $$\n$$ \\ln(N') \\Big|_{N(0)}^{N(t)} = -kt' \\Big|_0^t $$\n$$ \\ln(N(t)) - \\ln(N(0)) = -kt $$\n$$ \\ln\\left(\\frac{N(t)}{N(0)}\\right) = -kt $$\n$$ N(t) = N(0) \\exp(-kt) $$\n\nApplying this general solution to our specific populations, we get:\n$$ I(t) = I(0) \\exp(-k_I t) $$\n$$ D(t) = D(0) \\exp(-k_D t) $$\n\nThe problem provides the initial conditions at $t=0$ years: $I(0) = 120$ and $D(0) = 4880$ (in units of per-million-cells, which we can omit for calculation as they cancel in the final fraction). It also provides measurements at $t=3$ years: $I(3) = 60$ and $D(3) = 4392$. We can use this information to infer the rate constants $k_I$ and $k_D$.\n\nFirst, for the intact proviruses:\n$$ I(3) = I(0) \\exp(-k_I \\cdot 3) $$\n$$ 60 = 120 \\exp(-3k_I) $$\n$$ \\frac{60}{120} = \\frac{1}{2} = \\exp(-3k_I) $$\nTaking the natural logarithm of both sides:\n$$ \\ln\\left(\\frac{1}{2}\\right) = -3k_I $$\n$$ -\\ln(2) = -3k_I $$\n$$ k_I = \\frac{\\ln(2)}{3} \\text{ years}^{-1} $$\n\nNext, for the defective proviruses:\n$$ D(3) = D(0) \\exp(-k_D \\cdot 3) $$\n$$ 4392 = 4880 \\exp(-3k_D) $$\n$$ \\frac{4392}{4880} = \\frac{9}{10} = 0.9 = \\exp(-3k_D) $$\nTaking the natural logarithm of both sides:\n$$ \\ln(0.9) = -3k_D $$\n$$ k_D = -\\frac{\\ln(0.9)}{3} = \\frac{\\ln(1/0.9)}{3} = \\frac{\\ln(10/9)}{3} \\text{ years}^{-1} $$\n\nNow that we have the rate constants, we can compute the populations at $t=6$ years.\nFor the intact proviruses:\n$$ I(6) = I(0) \\exp(-k_I \\cdot 6) = 120 \\exp\\left(-\\frac{\\ln(2)}{3} \\cdot 6\\right) = 120 \\exp(-2\\ln(2)) = 120 \\exp(\\ln(2^{-2})) = 120 \\cdot 2^{-2} = 120 \\cdot \\frac{1}{4} = 30 $$\n\nFor the defective proviruses:\n$$ D(6) = D(0) \\exp(-k_D \\cdot 6) = 4880 \\exp\\left(-\\left(-\\frac{\\ln(0.9)}{3}\\right) \\cdot 6\\right) = 4880 \\exp(2\\ln(0.9)) = 4880 \\exp(\\ln(0.9^2)) = 4880 \\cdot (0.9)^2 = 4880 \\cdot 0.81 = 3952.8 $$\n\nFinally, we compute the fraction of the total proviral reservoir that is intact at $t=6$ years:\n$$ f(6) = \\frac{I(6)}{I(6) + D(6)} $$\n$$ f(6) = \\frac{30}{30 + 3952.8} = \\frac{30}{3982.8} $$\n$$ f(6) \\approx 0.007532308... $$\n\nRounding the result to four significant figures gives $0.007532$.\n\nBiological Interpretation:\nThe rate constant for intact proviruses, $k_I = \\frac{\\ln(2)}{3} \\approx 0.231 \\text{ years}^{-1}$, corresponds to a half-life of $t_{1/2,I} = \\frac{\\ln(2)}{k_I} = 3$ years. The rate constant for defective proviruses, $k_D = -\\frac{\\ln(0.9)}{3} \\approx 0.035 \\text{ years}^{-1}$, corresponds to a half-life of $t_{1/2,D} = \\frac{\\ln(2)}{k_D} \\approx 19.7$ years. The replication-competent (intact) reservoir decays significantly faster than the defective reservoir. This implies that over time on suppressive ART, the proviral landscape becomes increasingly dominated by defective, non-functional sequences. However, the absolute decay of the intact, replication-competent reservoir is slow. A half-life of $3$ years suggests that natural decay alone is insufficient for a functional cure within a patient's lifetime. For example, reducing the reservoir by a factor of $1000$ (just under $10$ half-lives) would require approximately $30$ years. This underscores the necessity for active \"shock and kill\" or other cure strategies that can accelerate the clearance of this persistent, replication-competent reservoir.",
            "answer": "$$\\boxed{0.007532}$$"
        }
    ]
}